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Background. Ivermectin is being considered for mass drug administration for malaria, due to its ability to kill mosquitoes 
feeding on recently treated individuals. In a recent trial, 3-day courses of 300 and 600 mcg/kg/day were shown to kill Anopheles mos-
quitoes for at least 28 days post-treatment when fed patients’ venous blood using membrane feeding assays. Direct skin feeding on 
humans may lead to higher mosquito mortality, as ivermectin capillary concentrations are higher. We compared mosquito mortality 
following direct skin and membrane feeding.
Methods. We conducted a mosquito feeding study, nested within a randomized, double-blind, placebo-controlled trial of 141 
adults with uncomplicated malaria in Kenya, comparing 3 days of ivermectin 300 mcg/kg/day, ivermectin 600 mcg/kg/day, or pla-
cebo, all co-administered with 3 days of dihydroartemisinin-piperaquine. On post-treatment day 7, direct  skin and membrane 
feeding assays were conducted using laboratory-reared Anopheles gambiae sensu stricto. Mosquito survival was assessed daily for 
28 days post-feeding.
Results. Between July 20, 2015, and May 7, 2016, 69 of 141 patients participated in both direct skin and membrane feeding (pla-
cebo, n = 23; 300 mcg/kg/day, n = 24; 600 mcg/kg/day, n = 22). The 14-day post-feeding mortality for mosquitoes fed 7 days post-treat-
ment on blood from pooled patients in both ivermectin arms was similar with direct skin feeding (mosquitoes observed, n = 2941) 
versus membrane feeding (mosquitoes observed, n = 7380): cumulative mortality (risk ratio 0.99, 95% confidence interval [CI] 
0.95–1.03, P = .69) and survival time (hazard ratio 0.96, 95% CI 0.91–1.02, P = .19). Results were consistent by sex, by body mass 
index, and across the range of ivermectin capillary concentrations studied (0.72–73.9 ng/mL).
Conclusions. Direct skin feeding and membrane feeding on day 7 resulted in similar mosquitocidal effects of ivermectin across 
a wide range of drug concentrations, suggesting that the mosquitocidal effects seen with membrane feeding accurately reflect those 
of natural biting. Membrane feeding, which is more patient friendly and ethically acceptable, can likely reliably be used to assess 
ivermectin’s mosquitocidal efficacy.
Clinical Trials Registration. NCT02511353.
Keywords. malaria; ivermectin; Anopheles gambiae; direct skin feeding; membrane feeding.
Mass drug administration (MDA) for malaria is the treatment of 
the entire eligible population in an endemic area, regardless of 
individuals’ infection statuses or whether they have symptoms, 
and is currently being evaluated in several countries to accelerate 
progress towards malaria transmission reduction and elimination 
[1–3]. The antimalarial dihydroartemisinin-piperaquine (DP) 
is most commonly used for MDA, because of its slow elimina-
tion, providing 4–6 weeks of post-treatment prophylaxis against 
new infections. Ivermectin is an antiparasitic drug, which also 
kills mosquitoes feeding on recently treated individuals. Adding 
ivermectin to DP has been proposed as an innovative tool to 
increase the impact of MDA for malaria, by killing mosquitoes 
before they become infective  (10–14  days after ingesting ma-
laria parasites) and by reducing overall mosquito numbers in the 
community [4–6]. However, the single-dose of 150–200 mcg/kg 
ivermectin used for onchocerciasis and lymphatic filariasis con-
trol has only a small and short-lived effect (<7 days) on mosquito 
mortality [5]. Ivermectin is documented to be remarkably well 
tolerated, even up to doses of 2000 mcg/kg [7, 8].
In a recent trial, high-dose, 3-day courses of ivermectin at 
300 and 600 mcg/kg/day, co-administered with DP, were shown 
applyparastyle “fig//caption/p[1]” parastyle “FigCapt”
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to kill Anopheles mosquitoes for at least 28  days post-treat-
ment when fed patients’ venous blood using membrane feeding 
assays [6]. Membrane feeding assays may, however, underesti-
mate the mosquitocidal effect of ivermectin in comparison to 
direct skin feeding, where mosquitoes bite the human subject 
directly, due to potential differences in ivermectin concentra-
tions between venous blood (used in membrane feeding) and 
blood in subdermal venules and arterioles (the main source of 
blood for mosquitoes during direct skin feeding). Ivermectin is 
known to accumulate in subcutaneous fat, dermal, and fascial 
tissue at 2- to 3-fold higher concentrations than in venous blood 
[9]. In the recent trial, ivermectin concentrations were 1.33-fold 
higher in capillary versus venous blood [10].
Ivermectin feeding studies with direct  skin feeding on a 
human [11] and cattle [12] have shown a longer mosquitocidal 
effect (>2 weeks) in comparison with other studies using mem-
brane feeding (<7 days) [13]. A single study, including 6 human 
subjects, compared direct skin and membrane feeding 4 hours 
after a single dose of ivermectin at 200 mcg/kg and found that 
mosquito mortality was higher after direct skin feeding (hazard 
ratio [HR]  1.73, 95% confidence interval [CI] 1.57–1.90, 
P = .0001) [14]. Any difference between feeding methods could 
have important implications for both pharmacokinetic-phar-
macodynamic [10] and population-level [15] models assessing 
the impact of ivermectin on mosquito mortality and, through 
MDA, on malaria transmission. To date, these models have 
relied on membrane feeding estimates of ivermectin’s mosqui-
tocidal efficacy.
We directly compared mosquito mortality following di-
rect skin feeding versus membrane feeding in our trial on 3-day 
ivermectin courses of 300 and 600 mcg/kg/day.
METHODS
Trial Design
Details of the trial design, procedures, and safety, efficacy, and 
pharmacokinetic-pharmacodynamic (PK-PD) results have 
been published elsewhere [5, 6, 10]. Briefly, the study was a 
randomized, double-blind, placebo-controlled, parallel 3-arm, 
superiority trial (ClinicalTrials.gov: NCT02511353). Adults 
with uncomplicated Plasmodium falciparum malaria in western 
Kenya (n = 141) were randomly assigned (1:1:1), stratified by 
sex and body mass index (BMI), to receive 3 days of ivermectin 
600 mcg/kg/day (n = 47), 300 mcg/kg/day (n = 48), or placebo 
(n = 46), all co-administered with 3 days of DP. The primary 
methodology used membrane feeding to assess the mosquito-
cidal efficacy of ivermectin. On day 7, the current nested sub-
study compared direct skin feeding versus membrane feeding.
Patients
All patients enrolled in the main trial were eligible to partic-
ipate in the current sub-study, provided they gave additional 
written consent for direct skin feeding [5]. Up until day 7, when 
direct skin feeding took place, participants were given the op-
portunity to ask questions, familiarize themselves with the 
procedures in the lab, make their decision, and/or change their 
minds. Participation or refusal to participate in the direct skin 
feeding sub-study did not affect patients’ participation in the 
main trial or their malaria treatment. After direct skin feeding, 
patients were provided a tube of hydrocortisone cream to take 
home to reduce possible itching.
Membrane Feeding Procedure
In accordance with a standard membrane feeding protocol [16], 
a 1 mL sample of the participant’s venous blood was drawn into 
a sodium-heparin–coated tube, preheated to 37.5°C. Within 
2 minutes, the blood was placed in a water-jacketed glass-bell 
parafilm membrane  feeding system, heated to 37.5°C, and 3 
cups of mosquitoes commenced feeding for 20 minutes. The 
follow-up lasted 28  days for mosquito survival (2 cups) and 
10 days for oocyst prevalence (1 cup).
Direct Skin Feeding Procedure
Immediately after the blood draw for membrane feeding, and in 
accordance with previous direct skin feeding studies examining 
infectivity [17], 1 cup of mosquitoes was placed directly on the 
skin of the participant and allowed to feed for 15 minutes. The 
follow-up lasted 28 days for mosquito survival.
General Insectary Procedures
For both methods, each feeding used new cups of 50, 3- to 5-day-
old, female, insectary-reared, infection-free, Anopheles gam-
biae sensu stricto. Kisumu-strain mosquitoes. Post-feeding, the 
number of mosquitoes with an engorged abdomen (fully fed) 
were counted and those with lean abdomens (semi- and unfed) 
were discarded. Each day, the number of dead mosquitoes were 
counted and removed until the end of the follow-up period (see 
feeding procedures above). After the initial feeding on human 
blood, the mosquitoes were kept in a temperature- and humidi-
ty-controlled insectary (27°C, 80%) with a fixed light-dark cycle 
(12h/12h) and were maintained ad libitum on 10% sugar feeds. 
Insectary staff assessing mosquito survival were blinded to all 
characteristics of the cups, including participant identification, 
study arm, duration between treatment and feeding, and feeding 
method.
Outcome Measures
The primary outcome was cumulative mosquito mortality 14 days 
after feeding (henceforth referred to as post-feeding) on blood 
taken from patients who had started the 3-day ivermectin and DP 
regimen 7 days earlier (henceforth referred to as post-treatment). 
The secondary outcome was the daily survival of mosquitoes up 
to day 14 post-feeding. Paired venous and capillary ivermectin 
plasma concentrations were collected on post-treatment days 
2–7; The predicted concentrations on day 7 were obtained from 
our previously-published PK-PD analysis [10].
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Statistical Analysis
The analysis was based on the intention-to-treat population. 
Only mosquito and pharmacokinetic data from participants 
that contributed to both direct skin and membrane feeding was 
included. Mosquito mortality was assessed for fully-fed mos-
quitoes. Cumulative mosquito mortality was analyzed using the 
generalized estimating equations (GEE) model, with a binomial 
distribution, log link function, the feeding method (direct skin 
or membrane) as the only predictor, and taking the cluster de-
sign into account. Risk ratios (RR) and their 95% confidence 
intervals were derived from the GEE model. The survival time 
of mosquitoes post-feeding was analyzed using Cox regres-
sion, with feeding method as the only predictor, and adjusted 
for mosquito clusters (using shared frailty with γ distribution) 
to derive HRs. For GEE models, analyses were based on data 
collected for approximately 100 mosquitoes (2 cups of 50) per 
participant for membrane feeding and 50 mosquitoes (1 cup of 
50)  per participant for direct  skin feeding. Additional mem-
brane-fed mosquitoes used for oocyst polymerase chain reac-
tion (1 cup of 50) were excluded from the GEE analyses on day 
14, as they had all been euthanized after 10 days of mosquito 
follow-up. For Cox models, analyses were based on data col-
lected from approximately 150 mosquitoes (3 cups of 50) per 
participant for membrane feeding and 50 mosquitoes (1 cup of 
50)  per participant for direct  skin feeding. This included the 
membrane-fed mosquitoes used for oocyst polymerase chain 
reaction (1 cup of 50), which were euthanized after 10 days and, 
therefore, contributed a maximum of 10 days of survival data. 
The above analyses were performed separately by treatment arm 
and pooled across the 2 ivermectin arms. Pearson’s correlation 
coefficients (ρ) were determined for mosquito mortality rate 
ratios (direct  skin versus membrane feeding) and ivermectin 
concentrations (capillary-venous ratios), and were stratified by 
known determinants of ivermectin pharmacokinetics (sex and 
BMI) [10]. Analyses were performed using Stata v14.2.
Ethics
All patients gave written informed consent to participate in the 
main trial and additional written informed consent to partici-
pate in direct skin feeding on day 7 post-treatment. The study 
was approved by the ethics committees of the participating 
institutions [5].
RESULTS
Between July 20, 2015, and May 7, 2016, 141 patients were ran-
domized to ivermectin 600 mcg/kg/day (n = 47), 300 mcg/kg/
day (n = 48), or placebo (n = 46). In total, 128 patients (90.8%) 
attended the primary outcome visit at 7  days post-treatment, 
of which 69 patients (54%) participated in both direct skin and 
membrane feeding (ivermectin 600 mcg/kg/day, n = 22; iver-
mectin 300 mcg/kg/day, n = 24; placebo, n = 23; Figure 1; Table 
1). All patients were treated per protocol, except two in the 600 
mcg/kg/day arm.
The proportion of mosquitoes that fully fed was higher for di-
rect skin feeding (2941/3446, 85.3%) versus membrane feeding 
(7380/10 368, 71.2%; RR 1.20, 95% CI 1.12–1.28; P < .0001); this 
did not differ by treatment arm for either method (Table 2).
Compared with membrane feeding, direct skin feeding was 
associated with similar 14-day post-feeding mosquito mor-
tality when fed on blood 7 days post-treatment, both in terms 
741 adults with malaria assessed for eligibility
600 excluded
540 did not meet eligibility criteria
60 declined to parcipate
47 assigned to ivermecn
600 mcg/kg/day for 3 days
48 assigned to ivermecn
300 mcg/kg/day for 3 days
46 assigned to placebo
43 received all 3 allocated doses 47 received all 3 allocated doses 46 received all 3 allocated doses
43 aended day 7 visit 41 aended day 7 visit 44 aended day 7 visit
22 parcipated in both direct skin 
and membrane feeding
24 parcipated in both direct skin 
and membrane feeding
23 parcipated in both direct skin 
and membrane feeding
141 randomized
Figure 1. Trial flowchart.
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of cumulative mortality (ivermectin 600 mcg/kg/day, RR 0.98, 
95% CI 0.90–1.06, P  =  .55; ivermectin 300 mcg/kg/day, RR 
1.01, 0.98–1.03, P =  .69; placebo RR 1.07, 0.88–1.29, P =  .51) 
and survival time (ivermectin 600 mcg/kg/day, HR 0.93, 0.86–
1.00, P = .05; ivermectin 300 mcg/kg/day, HR 1.01, 0.93–1.09, 
P = .80; placebo HR 1.03, 0.92–1.15, P = .58; Figure 2; Table 3). 
Similar results were seen upon pooling the two ivermectin arms 
(HR 0.96, 0.91–1.02, P = .19; RR 0.99, 0.95–1.03, P = .69).
Based on the previously published trial’s population PK-PD 
model [10], the predicted medians (5th–95th percentiles [p5–
p95]) of ivermectin concentrations in venous blood at day 7 
were 17.3 (2.87–43.0), 7.75 (1.58–18.7), and 11.3 (1.58–39.5) 
ng/mL for ivermectin 600 mcg/kg/day, 300 mcg/kg/day, and in 
the arms combined, respectively. The corresponding predicted 
capillary blood concentrations were 24.2 (6.04–58.6), 8.22 
(1.54–22.6), and 14.3 (p5–p95, 1.60–49.4; min–max 0.72–73.9) 
ng/mL, respectively. The capillary-venous ratio of the observed 
ivermectin plasma concentrations remained consistent from 
day 2 + 4 hours through day 7, near the population predicted 
median ratio of 1.33 (Figure 3) [10].
The median (p5–p95) mosquito mortality rates 
(deaths/100  days) per sample for each feeding method (both 
ivermectin arms pooled) at day 7 of the study were 24.1 (6.96–
50.0) for direct skin feeding and 24.0 (6.73–48.3) for membrane 
feeding. The ratio of direct skin versus membrane feeding mos-
quito mortality rates was not affected by patients’ ivermectin 
plasma concentrations or capillary-venous ratios within the 
ranges studied, either overall or when stratified by sex and BMI 
(Figure 4).
DISCUSSION
Direct  skin feeding and membrane feeding conducted at day 
7 post-treatment resulted in similar mosquitocidal effects of 
ivermectin. This was seen in each of the 300 and 600 mcg/kg/
day treatment arms separately  and when combined, was not 
dependent on patients’ ivermectin plasma concentrations or 
Table 1. Characteristics of Subjects That Participated in Both Direct-
skin and Membrane Feeding
 
Ivermectin  
600 mcg/kg/day  
 for 3 Days
(n = 22)
Ivermectin  
300 mcg/kg/day  
 for 3 Days
(n = 24)
Placebo
(n = 23)
Age, years 27.3 (7.4) 25.5 (7.5) 26.0 (5.0)
Sex
 Male 13 (59%) 16 (67%) 14 (61%)
 Female 9 (41%) 8 (33%) 9 (39%)
Body mass 
index, kg/m2
22.9 (3.4) 21.5 (3.0) 21.6 (2.6)
Data are shown as n (%) or mean (standard deviation). Baseline characteristics of subjects 
that participated in both direct skin and membrane feeding (n = 69) were similar to those 
of the other trial participants that did not (n = 72) [6].
Ta
bl
e 
2.
 
Pr
op
or
tio
n 
of
 F
ul
ly
 F
ed
 M
os
qu
ito
es
 A
fte
r D
ir
ec
t S
ki
n 
Fe
ed
in
g 
an
d 
M
em
br
an
e 
Fe
ed
in
g
Fe
ed
in
g 
M
et
ho
d
H
um
an
 S
ub
je
ct
s;
 M
os
qu
ito
es
 F
ul
ly
 F
ed
 (%
)a
R
is
k 
R
at
io
 (9
5%
 C
on
fid
en
ce
 In
te
rv
al
), 
P 
Va
lu
e
IV
M
-3
x6
00
IV
M
-3
x3
00
P
la
ce
bo
IV
M
-3
x6
00
 v
s 
P
la
ce
bo
IV
M
-3
x3
00
 v
s 
P
la
ce
bo
IV
M
-3
x6
00
 v
s 
IV
M
-3
x3
00
D
ire
ct
 s
ki
n
22
;
93
8/
10
96
 (8
5.
6)
24
;
10
15
/1
19
9 
(8
4.
7)
23
;
98
8/
11
51
 (8
5.
8)
1.
00
 (0
.8
9–
1.
11
), 
.9
5
0.
99
 (0
.8
8–
1.
10
), 
.8
0
1.
01
 (0
.9
1–
1.
12
), 
.8
4
M
em
br
an
e
22
;
25
84
/3
30
0 
(7
8.
3)
24
;
25
33
/3
61
3 
(7
0.
1)
23
;
22
63
/3
45
5 
(6
5.
5)
1.
20
 (0
.9
9–
1.
45
), 
.0
7
1.
07
 (0
.8
8–
1.
30
), 
.5
1
1.
12
 (0
.9
4–
1.
33
), 
.2
0
A
bb
re
vi
at
io
ns
: I
V
M
-3
x3
00
, i
ve
rm
ec
tin
 3
00
 m
cg
/k
g/
da
y 
fo
r 
3 
da
ys
; I
V
M
-3
x6
00
, i
ve
rm
ec
tin
 6
00
 m
cg
/k
g/
da
y 
fo
r 
3 
da
ys
.
a T
he
 n
um
be
r 
of
 m
os
qu
ito
es
 f
ul
ly
 fe
d 
ou
t 
of
 t
he
 n
um
be
r 
of
 m
os
qu
ito
es
 o
ffe
re
d 
a 
bl
oo
d 
m
ea
l.
D
ow
nloaded from
 https://academ
ic.oup.com
/cid/article-abstract/69/7/1112/5257992 by R
adboud U
niversity N
ijm
egen user on 04 June 2020
1116 • CID 2019:69 (1 October) • Smit et al
capillary-venous ratio, and was seen irrespective of whether 
mortality was assessed as a proportion or a rate. Membrane 
feeding, which is more patient friendly, can likely reliably be 
used to assess ivermectin’s mosquitocidal effects.
Although mosquito mortality was only assessed at a single time 
point post-treatment, on day 7, results may be applicable to earlier 
or later feeding time points. This is because the lack of difference in 
mosquito mortality between the 2 feeding methods was observed 
across the full range of ivermectin capillary concentrations tested 
(min–max, 0.72–73.9 ng/mL; Figure 4), with corresponding mos-
quito mortality rates (direct skin feeding: median 24.1 deaths/100 
days, p5–p95 6.96–50.0; membrane feeding: median 24.0, p5–
p95 6.73–48.3) covering nearly the entire mosquitocidal effect 
range found in the main trial (median effect E50 28.7 deaths/100 
days, Emin-Emax 3.9–53.4) [10]. Although differences between di-
rect skin and membrane feeding were not assessed for capillary 
concentrations above 73.9 ng/mL, the mosquito mortality by day 
14 at these concentrations (incidence rate ratio > 10.6) is near uni-
versal, making it unlikely that clinically  meaningful differences 
would exist between feeding approaches. Although it is pos-
sible that a differential effect between direct skin and membrane 
feeding is only evident at lower concentrations, when the mosqui-
tocidal effect is low, this is not suggested by our analyses, which 
show a similar lack of difference between the 2 feeding methods 
even at the lowest concentrations studied.
It is unclear why the higher concentration of ivermectin in 
capillary blood compared to venous blood—a capillary-venous 
plasma ratio of 1.33, which was consistent across the range of 
blood concentrations tested in the main trial (Figure 3) [10] 
does not translate to higher mosquito mortality in direct skin 
feeding. The surface area available for feeding was larger for 
direct  skin feeding (8 cm diameter of the cup exposed to the 
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938 317 85 58 44 19 1 0600 µg/kg/day, direct skin
2584 815 205 67 48 10 1 1600 µg/kg/day, membrane
1015 534 174 109 70 35 24 11300 µg/kg/day, direct skin
2533 1325 463 181 107 61 27 17300 µg/kg/day, membrane
988 764 660 583 427 271 138 64Placebo, direct skin
2263 1812 1590 958 694 419 223 88Placebo, membrane
Number at risk
0 4 8 12 16 20 24 28
Survival time (days)
Placebo,          HR 1.03 (0.92, 1.15), P = .58
300 µg/kg/day, HR 1.01 (0.93, 1.09), P = .80
600 µg/kg/day, HR 0.93 (0.86, 1.00), P = .05
Direct skin (dash) vs membrane (solid) feeding
Figure 2. Mosquito mortality, stratified by treatment arm and feeding method. Direct skin feeding is indicated by the dashed lines; membrane feeding is indicated by the 
solid lines. Ivermectin 600 mcg/kg/day is indicated by the green lines; ivermectin 300 mcg/kg/day is indicated by the red lines; and placebo is indicated by the blue lines. 
Mortality was measured following feeding on day 7 post-treatment. The hazard ratios (95% confidence interval, P value) of mortality during the 14 days post-feeding, com-
paring direct skin versus membrane feeding for each treatment arm, were adjusted for mosquito clusters. Abbreviation: HR, hazard ratio.
Table 3. Mosquito Mortality Following Direct Skin Feeding and Membrane Feeding
Treatment Group Human Subjects
Mosquito Mortality on Day 14 (%) Risk or Hazard Ratio (95% CI), P Value
Direct Skin Feeding Membrane Feedinga Model Direct Skin vs Membrane
IVM-3x600 22 890/938 (94.9) 1677/1729 (97.0) GEE RR 0.98 (0.90–1.06), .55
2514/2584 (97.3) Cox HR 0.93 (0.86–1.00), .052
IVM-3x300 24 938/1015 (92.4) 1573/1703 (92.4) GEE RR 1.01 (0.98–1.03), .69
2330/2533 (92.0) Cox HR 1.01 (0.93–1.09), .80
Placebo 23 503/988 (50.9) 706/1493 (47.3) GEE RR 1.07 (0.88–1.29), .51
999/2263 (44.1) Cox HR 1.03 (0.92–1.15), .58
Abbreviations: CI, confidence interval; GEE, generalized estimating equations; HR, hazard ratio; IVM-3x300, ivermectin 300 mcg/kg/day for 3 days; IVM-3x600, ivermectin 600 mcg/kg/day 
for 3 days; RR, risk ratio.
aGEE models used 2 cups of mosquitoes, followed for 14 days; Cox models used the same 2 cups, plus 1 cup, followed for 10 days, which were then euthanized for oocyst polymerase 
chain reaction.
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skin vs 1.8  cm diameter of the artificial membrane), possibly 
leading to less crowding and explaining the higher proportion 
of fully-fed mosquitoes in direct skin feeding. If capillary blood 
samples reflect the blood source of skin-fed mosquitoes and the 
concentration of ivermectin imbibed, counterbalancing forces 
must be at play. A possible explanation is that direct  skin  fed 
mosquitoes consumed a smaller blood volume than mem-
brane fed mosquitoes, despite all analyzed mosquitoes visually 
appearing to be fully fed. This was suggested in a previous study 
with Anopheles aquasalis, a Latin American malaria vector, that 
found a 48% difference in mean post-feeding weight between 
direct skin fed (0.040 mg, standard deviation 0.02) and mem-
brane  fed mosquitoes (0.059, standard deviation  0.02) [14]. 
Such a difference in blood-meal size may reflect differences in 
the blood flow between the 2 procedures or the energy involved 
in taking a blood meal, both of which might favor a larger blood 
meal in membrane feeding. Future studies could assess blood-
meal volumes following direct  skin and membrane feeding, 
for example by measuring the hemoglobin in fed mosquitoes. 
Furthermore, it is not clear whether other factors associated 
with skin feeding that are not present in the membrane feeds 
(eg, dermal immune mechanisms) could reduce ivermectin’s 
mosquitocidal effect with direct skin feeding.
Only one previous study has directly compared direct  skin 
versus membrane feeding [14]. This small study in 6 human 
subjects in Brazil used feeding assays conducted 4 hours after a 
single-dose of 200 mcg/kg (ie, Tmax, time of the maximum drug 
concentration in serum) and reported significantly higher mor-
tality of the Latin American malaria vector Anopheles aquasalis 
following direct skin feeding [14]. A single dose of ivermectin 
at 200 mcg/kg has a predicted plasma maximum drug concen-
tration (median, p5–p95) of 27 ng/mL (18.8–41.4) [5], which is 
within the 1.58–39.5 ng/mL range of the venous plasma concen-
trations tested in our current study. The HR following membrane 
feeding at 4 hours after this single 200 mcg/kg dose was 3.2, 
which is not that different from the 4.4 in the 300 mcg/kg/day 
arm in our study. It is not clear whether the differences between 
the 2 studies can be explained by differences in pharmacody-
namic factors (ie, ivermectin sensitivity of the Anopheles species) 
or pharmacokinetic factors, due to differences in study popula-
tions (ie, ethnic group and clinical indication; Kenyan patients 
with acute uncomplicated malaria versus Brazilian patients with 
other indications for ivermectin treatment) or differences in the 
timing of feeding post-treatment (ie, 7 days versus 4 hours after 
ingestion). It is also possible that the higher mosquito mortality 
observed with direct skin feeding in the Brazilian study reflects a 
chance finding, given the small number of subjects (n = 6).
As the relationship between ivermectin concentration, 
whether venous or capillary, and mosquitocidal effect has been 
previously established for membrane feeding [10] and the cur-
rent study shows no difference in mosquitocidal efficacy between 
direct  skin and membrane feeding with Anopheles Gambiae ss, 
future studies could consider using ivermectin concentration 
in either venous blood or in capillary blood obtained from fin-
ger-prick samples as a proxy of the potential mosquitocidal effect, 
without the need to invoke more labor-intensive and patient-un-
friendly membrane or direct skin feeding assays. The similarity in 
mosquitocidal efficacy between feeding methods also has impor-
tant implications for population-level models used to predict the 
impact of ivermectin MDA on malaria transmission [15]. Due 
to the sparse availability of direct skin feeding data, these models 
have relied on mosquitocidal efficacy estimates from membrane 
feeding, using either spiked blood [12, 13, 18, 19] or blood sam-
ples from humans [13]. Our results, which show that membrane 
feeding appears to be a good proxy for natural biting, strengthen 
the reliability of these existing models.
Our current nested sub-study was limited by the fact that it 
was only conducted at a single time point, at day 7 post-treat-
ment. Future studies could examine differences between 
direct skin and membrane feeding at lower and higher concen-
trations, at earlier or later time points post-treatment, and using 
both ivermectin and other endectocides, such as moxidectin, 
eprinomectin, fluralaner, and afoxolaner [20–22], which have 
different pharmacokinetics. Furthermore, the trial only assessed 
mosquito mortality and did not assess any possible sublethal 
effects, such as sporogony and oviposition (laying of eggs), 
which could be relevant, especially at low concentrations, and 
could be investigated in further studies. It is unknown whether 
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Figure 3. Capillary versus venous ratios of ivermectin plasma concentration 
during 2–7  days post-treatment. The open circles represent the capillary versus 
venous ratios of observed ivermectin plasma concentrations for each sample 
(n  =  177), taken from patients in the main trial contributing capillary samples 
(n  =  61) during 2–7  days post-treatment (maximum 4 samples/patient). The 
ball-whiskers indicate the median ± interquartile range per sampling day. The hori-
zonal line indicates a median ratio of 1.33 (5th–95th percentiles, 0.98–1.63), based 
on the trial’s simultaneous pharmacokinetic-pharmacodynamic population model 
[10]. Adapted from Smit et al [10].
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our results can be extrapolated to the pediatric population, be-
cause ivermectin pharmacokinetics in children, including the 
capillary-venous ratio, are not yet known.
In conclusion, both direct skin feeding and membrane feeding on 
day 7 resulted in similar mosquito mortality of Anopheles gambiae 
after ivermectin treatment across a wide range of drug concentra-
tions; this was similar by sex and BMI, suggesting that the mosqui-
tocidal effects observed with membrane feeding in the main trial 
depict those of natural biting. Membrane feeding, which is more 
patient-friendly and allows a larger number of mosquito observa-
tions, likely accurately reflects ivermectin’s mosquitocidal effects.
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Figure 4. Direct skin feeding versus membrane feeding ratios of mosquito mortality rates by ivermectin concentration and capillary-venous ratio at the time of feeding. 
The circles represent the observed 14-day mosquito mortality rate ratios of direct skin versus membrane feeding, performed at day 7 post-treatment for each patient that 
received ivermectin and consented to direct skin feeding (n = 46), plotted against their day 7 (A) predicted ivermectin capillary plasma concentration and (B) predicted cap-
illary versus venous ratio, using the trial’s simultaneous pharmacokinetic-pharmacodynamic population model [10]. (C) and (D) are as per (B), but now stratified by sex and 
body mass index, respectively. The lines indicate the linear fits. Abbreviation: BMI, body mass index; DF, direct skin feeding; MF, membrane feeding; mosq., mosquito; mort., 
mortality; pred., predicted.
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